X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs DIVIS LABORATORIES - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH DIVIS LABORATORIES PROCTER & GAMBLE HEALTH/
DIVIS LABORATORIES
 
P/E (TTM) x 60.7 32.3 187.7% View Chart
P/BV x 10.6 7.3 145.6% View Chart
Dividend Yield % 0.3 0.6 52.0%  

Financials

 PROCTER & GAMBLE HEALTH   DIVIS LABORATORIES
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-17
DIVIS LABORATORIES
Mar-18
PROCTER & GAMBLE HEALTH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,3581,142 118.9%   
Low Rs933533 175.0%   
Sales per share (Unadj.) Rs665.0146.6 453.7%  
Earnings per share (Unadj.) Rs56.633.0 171.2%  
Cash flow per share (Unadj.) Rs72.538.4 188.7%  
Dividends per share (Unadj.) Rs15.0010.00 150.0%  
Dividend yield (eoy) %1.31.2 109.7%  
Book value per share (Unadj.) Rs441.7222.8 198.2%  
Shares outstanding (eoy) m16.60265.47 6.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.75.7 30.1%   
Avg P/E ratio x20.225.3 79.9%  
P/CF ratio (eoy) x15.821.8 72.5%  
Price / Book Value ratio x2.63.8 69.0%  
Dividend payout %26.530.3 87.6%   
Avg Mkt Cap Rs m19,011222,318 8.6%   
No. of employees `0001.510.8 14.3%   
Total wages/salary Rs m1,6964,561 37.2%   
Avg. sales/employee Rs Th7,150.03,616.0 197.7%   
Avg. wages/employee Rs Th1,098.7423.8 259.3%   
Avg. net profit/employee Rs Th608.2814.9 74.6%   
INCOME DATA
Net Sales Rs m11,04038,915 28.4%  
Other income Rs m2401,134 21.1%   
Total revenues Rs m11,27940,049 28.2%   
Gross profit Rs m1,37612,617 10.9%  
Depreciation Rs m2641,425 18.5%   
Interest Rs m013 0.0%   
Profit before tax Rs m1,35212,313 11.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m5833,543 16.4%   
Profit after tax Rs m9398,770 10.7%  
Gross profit margin %12.532.4 38.4%  
Effective tax rate %43.128.8 149.8%   
Net profit margin %8.522.5 37.7%  
BALANCE SHEET DATA
Current assets Rs m7,52345,351 16.6%   
Current liabilities Rs m2,2536,507 34.6%   
Net working cap to sales %47.799.8 47.8%  
Current ratio x3.37.0 47.9%  
Inventory Days Days52127 41.2%  
Debtors Days Days4195 42.6%  
Net fixed assets Rs m1,24021,160 5.9%   
Share capital Rs m166531 31.3%   
"Free" reserves Rs m7,16758,625 12.2%   
Net worth Rs m7,33359,156 12.4%   
Long term debt Rs m00-   
Total assets Rs m9,91267,832 14.6%  
Interest coverage xNM926.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.6 194.1%   
Return on assets %9.512.9 73.2%  
Return on equity %12.814.8 86.4%  
Return on capital %20.820.8 99.6%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m1,01532,359 3.1%   
Fx outflow Rs m3,0439,042 33.6%   
Net fx Rs m-2,02823,317 -8.7%   
CASH FLOW
From Operations Rs m5377,759 6.9%  
From Investments Rs m-476-4,783 10.0%  
From Financial Activity Rs m-220-3,142 7.0%  
Net Cashflow Rs m-160-166 96.1%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 11.8 154.2%  
FIIs % 1.0 19.0 5.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.2 169.2%  
Shareholders   28,591 31,796 89.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  ABBOTT INDIA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Jul 19, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - UNICHEM LAB COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS